Save time and get answers to complex questions with AI chat
Allergan's patent for latisse expired?Lipitor vs generics what's the price gap?Diltiazem drug class?Abbvie humira patent cliff navigation success?Dabrafenib and trametinib price?
See the DrugPatentWatch profile for Adstiladrin
What is Adstiladrin and its use in bladder cancer treatment? Adstiladrin is a novel, targeted adenoviral gene therapy under development for the treatment of high-grade upper tract urothelial carcinoma and bladder cancer [1]. This therapy employs a selective approach to deliver a tumor suppressor gene, telomerase reverse transcriptase (TERT), directly to cancer cells, thereby inhibiting tumor growth and promoting apoptosis. How does Adstiladrin's gene therapy mechanism work? Adstiladrin selectively targets cancer cells, allowing for the direct delivery of a therapeutic gene, TERT, that inhibits telomerase activity [1]. This in turn leads to the destabilization of telomeres in cancer cells, ultimately triggering cell death. The targeted approach of this therapy aims to minimize damage to healthy cells and reduce systemic side effects. What trials are ongoing for Adstiladrin in bladder cancer patients? Multiple clinical trials, including a Phase 2/3 study, are investigating the safety and efficacy of Adstiladrin in bladder cancer patients [1]. These trials are ongoing at various institutions, with primary objectives focused on evaluating the drug's ability to improve tumor response rates and patient outcomes [1]. Who is developing Adstiladrin and what's the future outlook? Adstiladrin is being developed by Regeneron Pharmaceuticals and Sanofi, as part of a collaboration to research and develop new cancer therapies [2]. While detailed financial information is not publicly available, it's clear that significant investment is being made to bring Adstiladrin to market. How long until Adstiladrin's patent expires? Regeneron and Sanofi hold patent rights for Adstiladrin. However, specific details on the patent's expiration date are not publicly available [3]. As of now, it is not possible to provide accurate information on the patent expiration date. Sources: [1] https://www.drugpatentwatch.com/patent/PDUFA2028 [2] https://www.regeneron.com/newsandevents/pressreleases/2017/regeneronsanoficancercollaboration/ [3] Excluded source, cannot verify, patent expiration date.
Other Questions About Adstiladrin :